LabConnect

In This Issue

Billing

New billing system coming Q3 2021

Coagulation

- Fibrinogen, quantitative
- Thrombin time

Immunohistochemistry

• SS18-SSX

Referral Testing

- Paraneoplastic autoantibody evaluation, serum
- Paraneoplastic autoantibody evaluation, spinal fluid



Phone

612-863-4678 800-281-4379

Fax

612-863-4067



BILLING

New billing system coming Q3 2021

In Q3 of this year, Allina Health Laboratory will be transitioning from our current billing platform, XIFIN, to TELCOR.

The following changes will occur as a part of the transition:

- Clients using the XIFIN portal will be transitioned to the TELCOR portal
- Any clients not currently using our billing portal will have TELCOR portal access established
- Hard copy invoices will no longer be mailed
 - ♦ Invoices will be accessed via the TELCOR portal
- The look and layout of the monthly invoice will change
- Current processes for requesting additional billing information from clients will become a more automated process

As we get closer to the implementation and have more specific details, we will share them and provide any education needed.

COAGULATION

Fibrinogen, quantitative

Changing to a new lot of coagulation assay reagent requires thorough validation testing to establish a new mean normal reference value. This process occurs approximately every 12 months when a new lot of reagent has been made available by the instrumentation reagent vendor.

Effective May 18, 2021 the reference range for the Fibrinogen, quantitative assay (101/85384.0) changed.

Previous	NEW
200 - 450 mg/dL	233 - 384 mg/dL

Thrombin time

Changing to a new lot of coagulation assay reagent requires thorough validation testing to establish a new mean normal reference value. This process occurs approximately every 12 months when a new lot of reagent has been made available by the instrumentation reagent vendor.

Effective May 18, 2021 the reference range for the Thrombin time assay (510/85670.2) changed.

Previous	NEW
<20 seconds	<17 seconds

REFERRAL TESTING

Paraneoplastic autoantibody evaluation, serum

On May 11, 2021, the Paraneoplastic autoimmune evaluation, serum assay (8070/LAB8070) became obsolete.

Testing profiles are available for autoimmune encephalopathy, dementia, or epilepsy and are superior to the paraneoplastic panel for these disease states. The specific profiles include more biomarkers and provide reports that are more informative.

The alternate suggested test orders by disease state are:

- Dementia autoimmune evaluation, serum 12688/LAB12688
- Encephalopathy autoimmune evaluation, serum 12690/LAB12690
- Epilepsy autoimmune evaluation, serum 12692/LAB1269

Paraneoplastic autoantibody evaluation, spinal fluid

On May 11, 2021, the Paraneoplastic autoimmune evaluation, spinal fluid assay (8070/LAB8070) became obsolete.

Testing profiles are available for autoimmune encephalopathy, dementia, or epilepsy and are superior to the paraneoplastic panel for these disease states. The specific profiles include more biomarkers and provide reports that are more informative.

The alternate suggested test orders by disease state are:

- Dementia autoimmune evaluation, spinal fluid 12687/LAB12687
- Encephalopathy autoimmune evaluation, spinal fluid 12689/LAB12689
- Epilepsy autoimmune evaluation, spinal fluid 12691/LAB12691

IMMUNOHISTOCHEMISTRY

SS18-SSX

The Allina Health Laboratory Immunohistochemistry department is now offering the SS18-SSX stain.

- The SS18-SSX Is a Monoclonal antibody targeting the SS18-SSX fusion protein
 - Reported sensitivity of 87-95% with 100% specificity when strong diffuse nuclear positivity is present (expression in greater than 75% of tumor cells)
 - Decreased sensitivity has been reported in decalcified specimens, specimens with delayed tissue fixation, areas of necrosis and in areas of crush artifact
- Has a nuclear staining pattern



The AHL Immunohistochemistry requisition has been updated to include this new stain offering.